Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Mar 21, 2021 9:14pm
307 Views
Post# 32848146

Just my thoughts

Just my thoughts I just posted this on Claritas site...Thinking this over and over the past week but kept thoughts inside...I think we were bought out for our GVHD ....and the nitric oxide was more meat to the acquisition...Dec 2019 Bob did say he was in talks with multiple entities ...the Stero deal was to add more interest with their extended portfolio...but covid set in and out of nowhere we were shocked with the cancel of stero and new deal with NO lisence and buy of Salzman ....we went back to bargain table with more interest ....results of NO clinical trials in the newsmade us more valuable ....and our deal was done in Jan 2021 ...and can't overlook the deal of Jazz buying GW Pharma Feb 3/2021 for 7.2 billion ..forgot to mention ...500 million in sales less then 2yrs with their epilepsy cbd .. 90% ??of their revenue ... reason why i say bought by Claritasis i just don't see how Kly can start trading with new name unless funds were already in our hands ...new website...power team...milestone payouts ... then I just saw this and decided to come posts my thoughts ...this is imo...glta https://adisinsight.springer.com/drugs/800048735
<< Previous
Bullboard Posts
Next >>